Quoin Pharmaceuticals Ltd ADR (QNRX) — Titan Protect Analysis

QNRX

Quoin Pharmaceuticals Ltd ADR

Healthcare · ·

$4.49

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$9M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.57

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-231.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$32.50

+624% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Quoin Pharmaceuticals Ltd ADR

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical

https://quoinpharma.com

Country: United States Employees: 4 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.084

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0131

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.679

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-59.2%

Historical annualised return based on price data

Max Drawdown

-87.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$41.80

89% below the year high

52W Low

$4.55

-1% above the year low

Avg Volume

96,641

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-10.07

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

24.78

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-9,524,974

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-16,990,212

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$40.00

Target Median

$32.50

Target Low

$14.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go